Search - tctmd.com

Displaying 661 - 680 of 1137

Sort: Relevancy | Date

Presentation SCAI 2017

Watchman LAAO: Implant Procedure and Patient Management

Presenter: Chadi Alraies

May 11, 2017

Presentation ECHO 2017

Interventional Echocardiography II: PVL and LAA Closure

Presenter: Omar K. Khalique

April 02, 2017

Presentation SIF 2017

Watchman Imaging: The Echocardiographic Assessment

Presenter: Robert F. Burke

March 09, 2017

Presentation SIF 2017

LAA Closure: First or Second Line Therapy.

Presenter: Brij Maini

March 09, 2017

Presentation SIF 2017

LAA Closure with the WATCHMAN Device: A Perfect Case

Presenter: Ramon Quesada,

March 09, 2017

Presentation SIF 2017

How to Perform Watchman

Presenter: Steven J Yakubov

March 09, 2017

Presentation SIF 2017

Guidelines in Choosing Optimal Patient For Watchman

Presenter: Samir Kapadia

March 09, 2017

Presentation SIF 2017

Cardiac CTA for LAA Occlusion Planning and Follow Up

Presenter: Michael J. Rinaldi

March 08, 2017

Presentation JIM 2017

Appendix Closure is the Solution

Presenter: Horst Sievert

February 10, 2017

Presentation JIM 2017

Clinical Experience With LAmbre LAA CLOSURE System

Presenter: Horst Sievert

February 09, 2017

Presentation TCT 2016

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith

November 02, 2016

Presentation TCT 2016

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr.

November 02, 2016

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Advertisement

Watchman LAAO: Implant Procedure and Patient Management

Interventional Echocardiography II: PVL and LAA Closure

Watchman Imaging: The Echocardiographic Assessment

LAA Closure: First or Second Line Therapy.

LAA Closure with the WATCHMAN Device: A Perfect Case

How to Perform Watchman

Guidelines in Choosing Optimal Patient For Watchman

Cardiac CTA for LAA Occlusion Planning and Follow Up

Appendix Closure is the Solution

Clinical Experience With LAmbre LAA CLOSURE System

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content